Get the Stockscreener App
179.77
0.75%
1.33
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Quest Diagnostics Inc stock is traded at $179.77, with a volume of 810.20K.
It is up +0.75% in the last 24 hours and up +8.02% over the past month.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
See More
Previous Close:
$178.44
Open:
$178.94
24h Volume:
810.20K
Relative Volume:
0.77
Market Cap:
$20.10B
Revenue:
$9.54B
Net Income/Loss:
$841.00M
P/E Ratio:
24.16
EPS:
7.44
Net Cash Flow:
$1.02B
1W Performance:
+1.59%
1M Performance:
+8.02%
6M Performance:
+6.52%
1Y Performance:
+20.09%
1-Day Range:
$177.27
$180.37
1-Week Range:
$175.56
$180.37
52-Week Range:
$146.17
$182.38
Quest Diagnostics Inc Stock (DGX) Company Profile
Name
Quest Diagnostics Inc
Sector
Industry
Phone
(973) 520-2700
Address
500 PLAZA DRIVE, SECAUCUS
Compare DGX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DGX
Quest Diagnostics Inc
|
179.77 | 19.95B | 9.54B | 841.00M | 1.02B | 7.44 |
|
TMO
Thermo Fisher Scientific Inc
|
489.01 | 183.16B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
210.93 | 150.53B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
650.84 | 52.32B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
119.20 | 33.77B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
191.09 | 32.20B | 15.50B | 1.33B | 2.16B | 7.34 |
Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-02-25 | Initiated | Redburn Atlantic | Buy |
| Mar-04-25 | Downgrade | Citigroup | Buy → Neutral |
| Jan-06-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-17-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-10-24 | Resumed | Jefferies | Buy |
| Oct-23-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Aug-28-24 | Resumed | Evercore ISI | In-line |
| Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
| Feb-26-24 | Initiated | Leerink Partners | Market Perform |
| Feb-07-24 | Upgrade | Jefferies | Hold → Buy |
| Jan-03-24 | Initiated | Barclays | Equal Weight |
| Dec-12-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-29-23 | Initiated | Piper Sandler | Neutral |
| May-02-23 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-03-23 | Upgrade | Citigroup | Sell → Neutral |
| Jan-23-23 | Initiated | Evercore ISI | In-line |
| Nov-17-22 | Downgrade | Citigroup | Neutral → Sell |
| Aug-22-22 | Resumed | Morgan Stanley | Equal-Weight |
| Apr-04-22 | Downgrade | Citigroup | Buy → Neutral |
| Feb-23-22 | Downgrade | UBS | Buy → Neutral |
| Feb-02-22 | Downgrade | Jefferies | Buy → Hold |
| Jan-28-22 | Downgrade | Deutsche Bank | Buy → Hold |
| May-04-21 | Upgrade | UBS | Neutral → Buy |
| Mar-12-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-21-20 | Upgrade | Argus | Hold → Buy |
| Jul-29-20 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Jul-14-20 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-09-20 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Jun-02-20 | Upgrade | Deutsche Bank | Hold → Buy |
| Apr-28-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-27-20 | Upgrade | Citigroup | Neutral → Buy |
| Apr-27-20 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Mar-27-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-19-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Jul-15-19 | Downgrade | Goldman | Neutral → Sell |
| Apr-02-19 | Upgrade | Jefferies | Hold → Buy |
| Mar-18-19 | Resumed | Credit Suisse | Neutral |
| Jan-31-19 | Downgrade | Argus | Buy → Hold |
| Jan-17-19 | Initiated | UBS | Neutral |
| Jan-03-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Dec-03-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Nov-30-18 | Downgrade | Goldman | Buy → Neutral |
View All
Quest Diagnostics Inc Stock (DGX) Latest News
Quest Diagnostics Introduces Testing for Oropouche Virus - Eastern Progress
Quest Diagnostics to Speak at the Baird 2025 Global Healthcare Conference - Eastern Progress
Quest Diagnostics to Speak at the Baird 2025 Global Healthcare C - GuruFocus
Leading Diagnostics Provider Quest Diagnostics CEO to Share Market Insights at Baird Healthcare Conference - Stock Titan
Here's Why Quest Diagnostics (DGX) is a Strong Growth Stock - Yahoo Finance
Quest Diagnostics Declares Quarterly Cash Dividend, Payable on October 20, 2025 - MarketScreener
Quest Diagnostics Declares Quarterly Cash Dividend of $0.80 per Share - AInvest
Medical Testing Giant Quest Diagnostics Maintains $0.80 Quarterly Dividend Payout - Stock Titan
Published on: 2025-08-12 17:41:01 - sundaytimes.kr
Quest Diagnostics acquires Fresenius lab assets for dialysis - NJBIZ
Major Clinical Trials Launch: New Blood Test Could Transform Post-Surgery Cancer Detection - Stock Titan
Quest Diagnostics (DGX) Insider Plans $968k Share Sale – Form 144 | SBS SEC FilingForm 6-K - Stock Titan
What to Expect From Quest Diagnostics' Q2 2025 Earnings Report - MSN
Quest Diagnostics Completes Acquisition of Clinical Testing Assets from Fresenius Medical Care - MarketScreener
Quest Diagnostics Takes Over Fresenius Labs, Set to Serve 200,000 Dialysis Patients Annually - Stock Titan
How many analysts rate Quest Diagnostics Incorporated as a “Buy”Get exclusive market analysis for investors - Jammu Links News
What is Quest Diagnostics Incorporated company’s growth strategyTremendous gains - Jammu Links News
Quest Diagnostics Incorporated Stock Analysis and ForecastFree Predictions - Jammu Links News
What are the technical indicators suggesting about Quest Diagnostics IncorporatedMaximize your returns with expert insights - Jammu Links News
What catalysts could drive Quest Diagnostics Incorporated stock higher in 2025Turbocharged investment results - Jammu Links News
Quest Diagnostics Raises 2025 Guidance - AOL.com
Quest Diagnostics Insider Selling: A Signal of Caution or a Strategic Move Amid Strong Fundamentals? - AInvest
Published on: 2025-08-01 19:05:55 - metal.it
Is Quest Diagnostics Incorporated stock overvalued or undervaluedFinancial News Updates Backed By Experts - Jammu Links News
Earnings visualization tools for Quest Diagnostics IncorporatedVerified Signal From Chart Patterns Detected - metal.it
Drug Abuse Testing Market Forecast and Company Analysis - GlobeNewswire
Drug Abuse Testing Market Forecast and Company Analysis Report 2025-2033 Featuring Danaher, LabCorp, Abbott, Quest Diagnostics, Thermo Fisher Scientific, F. Hoffmann-La Roche, Bio-Rad, Medtronic - Yahoo Finance
Quest Diagnostics Breakthrough: New Long-Read DNA Test Revolutionizes Ataxia Movement Disorder Detection - Stock Titan
North America Autoimmune Disease Diagnostics Market Report - GlobeNewswire
North America Autoimmune Disease Diagnostics Market Report 2025-2033 Featuring Bio-Rad, Abbott, Roche, Quest Diagnostics, Thermo Fisher Scientific, BioMerieux, Myriad Genetics, Siemens Healthineers - Yahoo Finance
What makes Quest Diagnostics Incorporated stock price move sharplyTrade Setups With Clear Risk Limits Highlighted - metal.it
Why Quest Diagnostics (DGX) is a Top Growth Stock for the Long-Term - sharewise.com
What is the risk reward ratio of investing in Quest Diagnostics Incorporated stockInvest smarter with real-time trading alerts - jammulinksnews.com
Why is Quest Diagnostics Incorporated stock attracting strong analyst attentionMarket-beating performance - Jammu Links News
Published on: 2025-07-28 06:28:08 - jammulinksnews.com
Deutsche Bank Aktiengesellschaft Issues Positive Forecast for Quest Diagnostics (NYSE:DGX) Stock Price - MarketBeat
What analysts say about Quest Diagnostics Incorporated stockDynamic growth stocks - PrintWeekIndia
How high can Quest Diagnostics Incorporated stock price go in 2025High-performance investment picks - jammulinksnews.com
Quest and CVS test co-location strategy in Rhode Island - The Business Journals
Quest Diagnostics Trading Volume Drops 31.43% to $364 Million Ranking 317th Despite Stock Price Rise - AInvest
Options Corner: Quest Diagnostics' Post-Earnings Digestion Drama Opens A Science-Backed Opportunity - inkl
Quest Diagnostics’ revenue up 15.2% to USD 2.76B in Q2 2025 - Medical Buyer
Barclays Reaffirms Their Hold Rating on Quest Diagnostics (DGX) - The Globe and Mail
Decoding Quest Diagnostics Inc (DGX): A Strategic SWOT Insight - GuruFocus
Quest Diagnostics Incorporated's (NYSE:DGX) Shares May Have Run Too Fast Too Soon - 富途牛牛
Quest Diagnostics (DGX) Price Target Raised by UBS, Rating Maint - GuruFocus
Quest Diagnostics Lifts Outlook As Testing Demand Grows - Finimize
U.S. DTC Wellness Testing Market Forecast to 2030: A $1.91 - GlobeNewswire
Quest Diagnostics (DGX) Price Target Raised by Deutsche Bank Ana - GuruFocus
Quest Diagnostics Reports Second Quarter 2025 Financial Results; Raises Guidance for Full Year 2025 - ADVFN Brasil
Quest Diagnostics Incorporated (NYSE:DGX) Q2 2025 Earnings Call Transcript - Insider Monkey
Quest Diagnostics Inc Stock (DGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.89%
0.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):